GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets closed

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
67.50-0.01 (-0.01%)
At close: 4:00PM EDT

67.45 -0.05 (-0.07%)
After hours: 6:52PM EDT

People also watch
CELGBIIBAMGNREGNBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close67.51
Open67.11
Bid67.45 x 1900
Ask67.72 x 2000
Day's Range66.97 - 67.82
52 Week Range65.38 - 103.10
Volume5,454,938
Avg. Volume10,595,578
Market Cap88.23B
Beta0.98
PE Ratio (TTM)6.79
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.08%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters8 hours ago

    Gilead hepatitis C drug patent faces European challenge

    International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir is sold by the U.S. drugmaker as Sovaldi and is included in other hepatitis C medicines such as Harvoni and Epclusa. The treatment is transforming the fight against the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier.

  • Investopedia9 hours ago

    Gilead’s Hep C Bestseller Faces Patent Dispute (GILD)

    Sovaldi is facing another patent challenge case in Europe by two international organizations

  • Better Buy: Celgene Corporation vs. Gilead Sciences
    Motley Fool9 hours ago

    Better Buy: Celgene Corporation vs. Gilead Sciences

    Gilead Sciences and Celgene are two of the most successful companies in biotech, but which stock is the better buy right now?